VacZine Analytics  
MarketVIEW: Shigella vaccines

Published: January 2016

Shigella are a highly infectious Gram-negative, non-sporulating, facultative anaerobic bacteria. They produce toxins, which cause a clinical presentation known as Shigellosis. Shigellosis comprises of systemic symptoms such as fever, headache, malaise, anorexia and occasional vomiting. Although shigellosis in otherwise healthy individuals is generally self-limiting, persistent diarrhoea in young children can be serious with the additional risk of seizures, haemolytic uraemic syndrome and other rare complications, which include encephalopathy. Most importantly, Shigella is the fifth most common known cause of diarrhoeal death in children aged <5 years, mostly in the developing world. In 1999, there were estimated to be 164.7 million cases of shigellosis annually globally in 1999, with 1.1 million deaths (WHO Figures).

A Shigella vaccine that can protect against all strains that produce clinically important disease is needed (i.e. a multivalent vaccine). International agencies such as PATH, WHO, and major national agencies such as the NIH are co-funding vaccine development to speed the development of safe, effective and affordable vaccines against Shigella. Some candidates e.g. WRAIR, GSK and PATH are in active clinical development.

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value of Shigella vaccines across endemic and travelers markets to 2035. Each model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates. LO/BASE/HI forecast scenarios are included based upon a risk classification of countries in terms of Shigella spp. disease incidence. An up to date review is also given for latest disease background and epidemiology, along with current R&D status.

THIS PRODUCT IS A EXECUTIVE PRESENTATION AND ONE FORECAST MODEL

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV067 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2016 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains